ANI Pharmaceuticals Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANI Pharmaceuticals stock.
View analyst ratings for ANI Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given ANI Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ANI Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ANI Pharmaceuticals.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Thursday, August, 5th. The specialty pharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.51 by $0.16. ANI Pharmaceuticals had a negative net margin of 8.07% and a positive trailing twelve-month return on equity of 17.57%. During the same quarter in the previous year, the firm earned $0.69 EPS.
View ANI Pharmaceuticals' earnings history.

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ANIP shares have decreased by 24.6% and is now trading at $28.89.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued twelve-month price targets for ANI Pharmaceuticals' shares. Their forecasts range from $60.00 to $60.00. On average, they expect ANI Pharmaceuticals' stock price to reach $60.00 in the next year. This suggests a possible upside of 107.7% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ANI Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Day One Biopharmaceuticals (DAWN), Generation Bio (GBIO), Arcturus Therapeutics (ARCT), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), Aerpio Pharmaceuticals (ARPO), Zealand Pharma A/S (ZEAL), Kura Oncology (KURA), COMPASS Pathways (CMPS), Vectura Group (VEGPF), Kronos Bio (KRON), Travere Therapeutics (TVTX), Madrigal Pharmaceuticals (MDGL) and PMV Pharmaceuticals (PMVP).
View all of ANIP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.50%), Vanguard Group Inc. (5.01%), Dimensional Fund Advisors LP (3.55%), State Street Corp (3.13%), Thompson Siegel & Walmsley LLC (3.08%) and Goldman Sachs Group Inc. (2.83%). Company insiders that own ANI Pharmaceuticals stock include Patrick D Walsh and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Renaissance Technologies LLC, Vanguard Group Inc., Prudential Financial Inc., Victory Capital Management Inc., Bank of New York Mellon Corp, and Legal & General Group Plc.
View insider buying and selling activity for ANI Pharmaceuticals or view top insider-selling stocks.

ANIP stock was bought by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., GSA Capital Partners LLP, First Wilshire Securities Management Inc., Deutsche Bank AG, Geode Capital Management LLC, and Public Sector Pension Investment Board. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals or or view top insider-buying stocks.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIP stock can currently be purchased for approximately $28.89.

ANI Pharmaceuticals has a market capitalization of $368.69 million and generates $208.48 million in revenue each year. The specialty pharmaceutical company earns $-22,550,000.00 in net income (profit) each year or $2.87 on an earnings per share basis.

ANI Pharmaceuticals employs 369 workers across the globe.

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

ANI Pharmaceuticals is headquartered at 210 Main Street West, Baudette MN, 56623.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at (218) 634-3500 or via email at [email protected]